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Thioridazine (see p. 46 of this issue) is such a drug. 2, 3 The QT interval in the ECG for most part represents the electrical 'recharging' of the cardiac myocytes after their depolarisation which initiates systole. This interval is not a passive resting period for the cells but an active, highly coordinated orchestration of numerous transmembranous ion channels that open and close in a specific sequence. A change in activity of these ion channels, due either to a genetic defect resulting in a channelopathy or to 'promiscuity' of the ion channels in allowing various drugs and not only ions to enter the channel, can lead to a marked slowing of repolarisation particularly in the M-cells situated between the epicardial and endocardial myocytes of the ventricular wall. 4 Not only may the QT become prolonged but voltage differences in the different layers of the heart may trigger after-depolarisations, polymorphic ventricular tachycardia, usually described as torsade de pointes, and even the total chaotic rhythm of ventricular fibrillation, the lethal arrhythmia that only defibrillation can reverse. The side-effects of drugs that interfere with ion channels may therefore present with silent ECG abnormalities, palpitations, syncope or sudden death. The study reported in this journal confirms that thioridazine is a drug that can have a significant effect on the ECG. 2, 5 Clearly, the best option would be to avoid all drugs that have the potential for prolonging QT. Unfortunately, this solution is not always possible: the drugs may be highly effective in treating the condition for which they are marketed, the drugs may be the cheaper alternative, or there may be no similar non-QT-lengthening drug available.
Furthermore, the arrhythmic complications of the drugs may be rare and may have been missed by pre-release testing and only identified by careful post-marketing surveillance.
Can the side-effects of a QT-prolonging drug be predicted or Various patient conditions that reduce the 'recharging' or repolarisation reserve of cardiac myocytes increase the risk of arrhythmias. These conditions include heart failure and electrolyte abnormalities such as hypokalaemia, which may be the result of diuretic use, diarrhoea or bulimia. 4, 6 Interestingly, the finding that sudden death is more frequent among psychiatric patients in general and among those on antipsychotics in particular is not new. 
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